Literature DB >> 8215293

In vitro postantibiotic effect following repeated exposure to imipenem, temafloxacin, and tobramycin.

B J McGrath1, C R Marchbanks, D Gilbert, M N Dudley.   

Abstract

The postantibiotic effect (PAE) following three consecutive 2-h exposures to imipenem, temafloxacin, and tobramycin was determined in Pseudomonas aeruginosa. A PAE and a bactericidal effect were consistently observed for imipenem following each cycle of drug exposure and regrowth. In contrast, the PAE increased with repeated exposure with temafloxacin (1.8 to > 5 h), but disappeared with tobramycin by the third exposure (0.9 to 0 h). These data show that the in vitro PAE may change within a strain following multiple cycles of drug exposure and bacterial regrowth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215293      PMCID: PMC188053          DOI: 10.1128/AAC.37.8.1723

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design.

Authors:  S C Ebert; W A Craig
Journal:  Infect Control Hosp Epidemiol       Date:  1990-06       Impact factor: 3.254

2.  Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.

Authors:  I Odenholt-Tornqvist
Journal:  Scand J Infect Dis Suppl       Date:  1989

3.  Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

Authors:  G L Daikos; G G Jackson; V T Lolans; D M Livermore
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli.

Authors:  B Fantin; S Ebert; J Leggett; B Vogelman; W A Craig
Journal:  J Antimicrob Chemother       Date:  1991-06       Impact factor: 5.790

5.  Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

6.  In vivo postantibiotic effect in a thigh infection in neutropenic mice.

Authors:  B Vogelman; S Gudmundsson; J Turnidge; J Leggett; W A Craig
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

  6 in total
  6 in total

1.  Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.

Authors:  J G den Hollander; J W Mouton; M P van Goor; F P Vleggaar; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  L Licata; C E Smith; R M Goldschmidt; J F Barrett; M Frosco
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

4.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

5.  Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.

Authors:  Alasdair P MacGowan; Karen E Bowker; Alan R Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

6.  Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.

Authors:  J A Karlowsky; G G Zhanel; R J Davidson; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.